Evidence map›Paper›PMID 40208246›Full record

ArticleeLife2025

Mechanistic insight for T-cell exclusion by cancer-associated fibroblasts in human lung cancer.

Joseph Ackermann, Chiara Bernard, Philemon Sirven, Helene Salmon, Massimiliano Fraldi, Martine D Ben Amar

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Targeting the Barriers Driving Immune Exclusion.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph AckermannLaboratoire Jean Perrin, Sorbonne Université, Paris, France.ORCID https://orcid.org/0000-0001-9218-6655
Chiara BernardDepartment of Structures for Engineering and Architecture, University of Naples "Federico II", Naples, Italy.
Philemon SirvenInstitut Curie, PSL Research University, INSERM, Paris, France.
Helene SalmonInstitut Curie, PSL Research University, INSERM, Paris, France.
Massimiliano FraldiLaboratoire de Physique de l'Ecole normale supérieure, ENS, Université PSL, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.
Martine D Ben AmarLaboratoire de Physique de l'Ecole normale supérieure, ENS, Université PSL, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.ORCID https://orcid.org/0000-0001-9132-2053

Funding

Agence Nationale de la Recherche ANR-20-CE13-0031Inserm Transfert ITMO-PCSIInserm Transfert MCMP 2022Ministry of University and Research 2022ATZCJN AMPHYBIA - CUP E53D23003040006
6 · The paper itself

Abstract

The tumor stroma consists mainly of extracellular matrix, fibroblasts, immune cells, and vasculature. Its structure and functions are altered during malignancy: tumor cells transform fibroblasts into cancer-associated fibroblasts, which exhibit immunosuppressive activities on which growth and metastasis depend. These include exclusion of immune cells from the tumor nest, cancer progression, and inhibition of T-cell-based immunotherapy. To understand these complex interactions, we measure the density of different cell types in the stroma using immunohistochemistry techniques on tumor samples from lung cancer patients. We incorporate these data into a minimal dynamical system, explore the variety of outcomes, and finally establish a spatio-temporal model that explains the cell distribution. We reproduce that cancer-associated fibroblasts act as a barrier to tumor expansion, but also reduce the efficiency of the immune response. Our conclusion is that the final outcome depends on the parameter values for each patient and leads to either tumor invasion, persistence, or eradication as a result of the interplay between cancer cell growth, T-cell cytotoxicity, and fibroblast activity. However, despite the existence of a wide range of scenarios, distinct trajectories, and patterns allow quantitative predictions that may help in the selection of new therapies and personalized protocols.

Indexed as

Cancer-Associated FibroblastsFibroblastsLung NeoplasmsT-LymphocytesHumansTumor Microenvironmentcancer biologydynamical systemhumanimmune responselung cancermixture modelOnsager's variational principlephysics of living systemstumor microenvironment

Identifiers

PMID40208246
PMCPMC11984955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.